Biotech · Public company · Hampton, NJ, US
Celldex Therapeutics, Inc.
Ticker CLDX · SEC CIK 0000744218
Track this companyFree. Adds Celldex Therapeutics, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials2513 recruiting or active
Pipeline programs8From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availableNo recent cash burn filed
Pipeline8
- barzolvolimabPhase 3 · Chronic Spontaneous UrticariaClinicalTrials.gov · fetched Nov 12, 2026
- BarzolvolimabPhase 3 · Chronic Inducible UrticariaClinicalTrials.gov · fetched Nov 12, 2026
- barzolvolimabPhase 2 · Prurigo NodularisClinicalTrials.gov · fetched Nov 12, 2026
- barzolvolimabPhase 2 · Eosinophilic EsophagitisClinicalTrials.gov · fetched Nov 12, 2026
- BarzolvolimabPhase 2 · Atopic DermatitisClinicalTrials.gov · fetched Nov 12, 2026
- CDX-585Phase 1 · Non-small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- CDX-622Phase 1 · Healthy ParticipantsClinicalTrials.gov · fetched Nov 12, 2026
- CDX-622Phase 1 · Mild to Moderate AsthmaClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials25
- A Study of CDX-622 in Participants With Mild to Moderate AsthmaPHASE1 · RECRUITING · started Jun 1, 2026ClinicalTrials.gov NCT07330778 · fetched Nov 12, 2026
- A Study to Investigate Efficacy, Safety and Tolerability of Barzolvolimab Versus Placebo in Adults With Cold Induced Urticaria and Symptomatic Dermographism Inadequately Controlled by H1-antihistamines (EMBARQ - ColdU and SD)PHASE3 · RECRUITING · started Jan 15, 2026ClinicalTrials.gov NCT07266402 · fetched Nov 12, 2026
- Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants With Chronic Spontaneous UrticariaPHASE3 · ENROLLING_BY_INVITATION · started Nov 25, 2025ClinicalTrials.gov NCT07256392 · fetched Nov 12, 2026
- A Study of Barzolvolimab in Patients With Atopic DermatitisPHASE2 · ACTIVE_NOT_RECRUITING · started Dec 18, 2024ClinicalTrials.gov NCT06727552 · fetched Nov 12, 2026
- A Phase I Study of CDX-622PHASE1 · COMPLETED · started Nov 1, 2024ClinicalTrials.gov NCT06650761 · fetched Nov 12, 2026
- A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)PHASE3 · ACTIVE_NOT_RECRUITING · started Jul 19, 2024ClinicalTrials.gov NCT06455202 · fetched Nov 12, 2026
- A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous UrticariaPHASE3 · ACTIVE_NOT_RECRUITING · started Jul 11, 2024ClinicalTrials.gov NCT06445023 · fetched Nov 12, 2026
- A Study of Barzolvolimab in Patients With Prurigo NodularisPHASE2 · ACTIVE_NOT_RECRUITING · started Apr 12, 2024ClinicalTrials.gov NCT06366750 · fetched Nov 12, 2026
- Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian CancerPHASE2 · RECRUITING · started Mar 12, 2024ClinicalTrials.gov NCT05231122 · fetched Nov 12, 2026
- A Study of CDX-0159 in Patients With Eosinophilic EsophagitisPHASE2 · COMPLETED · started Jun 1, 2023ClinicalTrials.gov NCT05774184 · fetched Nov 12, 2026
- A Study of CDX-585 in Patients With Advanced MalignanciesPHASE1 · COMPLETED · started May 11, 2023ClinicalTrials.gov NCT05788484 · fetched Nov 12, 2026
- Personalized TCR-T: Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T)PHASE1 · ACTIVE_NOT_RECRUITING · started Apr 3, 2023ClinicalTrials.gov NCT05349890 · fetched Nov 12, 2026
- A Study of CDX-0159 in Patients With Chronic Inducible UrticariaPHASE2 · COMPLETED · started Jun 28, 2022ClinicalTrials.gov NCT05405660 · fetched Nov 12, 2026
- A Phase 2 Study of CDX-0159 in Patients With Chronic Spontaneous UrticariaPHASE2 · COMPLETED · started May 19, 2022ClinicalTrials.gov NCT05368285 · fetched Nov 12, 2026
- CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast CancerPHASE1 · RECRUITING · started Apr 20, 2022ClinicalTrials.gov NCT05029999 · fetched Nov 12, 2026
- NeoVax + CDX-301 and Nivolumab or Pembrolizumab in MelanomaPHASE1 · ACTIVE_NOT_RECRUITING · started Jan 3, 2022ClinicalTrials.gov NCT04930783 · fetched Nov 12, 2026
- Immunologic Effects of CDX-301 and CDX-1140 in Resectable Pancreatic Cancer PatientsPHASE2 · TERMINATED · started Aug 13, 2021ClinicalTrials.gov NCT04536077 · fetched Nov 12, 2026
- Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists In Patients With Melanoma (Including Ocular Melanoma)PHASE1_PHASE2 · COMPLETED · started Sep 28, 2020ClinicalTrials.gov NCT04364230 · fetched Nov 12, 2026
- DC Migration Study to Evaluate TReg Depletion In GBM Patients With and Without VarlilumabPHASE2 · ACTIVE_NOT_RECRUITING · started Aug 26, 2020ClinicalTrials.gov NCT03688178 · fetched Nov 12, 2026
- Converting HR+ Breast Cancer Into an Individualized VaccinePHASE2 · RECRUITING · started Mar 17, 2020ClinicalTrials.gov NCT03804944 · fetched Nov 12, 2026
- Platform Study for Prostate Researching Translational Endpoints Correlated to Response to Inform Use of Novel CombinationsPHASE1 · COMPLETED · started Jun 21, 2019ClinicalTrials.gov NCT03835533 · fetched Nov 12, 2026
- Vaccination With Flt3L, Radiation, and Poly-ICLCPHASE1_PHASE2 · COMPLETED · started Apr 5, 2019ClinicalTrials.gov NCT03789097 · fetched Nov 12, 2026
- DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid LeukemiaPHASE1 · COMPLETED · started Mar 27, 2018ClinicalTrials.gov NCT03358719 · fetched Nov 12, 2026
- A Study of Varlilumab and IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade Glioma (LGG)PHASE1 · TERMINATED · started Apr 3, 2017ClinicalTrials.gov NCT02924038 · fetched Nov 12, 2026
- FLT3 Ligand Immunotherapy and Stereotactic Radiotherapy for Advanced Non-small Cell Lung CancerPHASE2 · COMPLETED · started Jul 1, 2016ClinicalTrials.gov NCT02839265 · fetched Nov 12, 2026
SEC filings12
- 10-Q · 10-QSEC EDGAR · filed Nov 5, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Nov 5, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Sep 22, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Aug 6, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Aug 6, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Jul 15, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Jun 26, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed May 7, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed May 7, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Apr 2, 2026 · fetched Nov 12, 2026
- 10-K · 10-KSEC EDGAR · filed Feb 25, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Feb 25, 2026 · fetched Nov 12, 2026